PepGen Inc. (PEPG) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

PepGen Inc. (PEPG)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.75

-0.05 (-1.79%)

At close: Jan 14, 2025, 3:59 PM

2.72

-1.09%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	2.19
Market Cap	89.64M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.98
PE Ratio (ttm)	-0.92
Forward PE	n/a
Analyst	Buy

Ask	4.35
Volume	113,771
Avg. Volume (20D)	169,308
Open	2.80
Previous Close	2.80
Day's Range	2.67 - 2.85
52-Week Range	2.67 - 19.30
Beta	undefined

About PEPG

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 6, 2022

Employees 76

Stock Exchange NASDAQ

Ticker Symbol PEPG

Website https://www.pepgen.com

Analyst Forecast

According to 3 analyst ratings, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 336.36% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-3.63%

PepGen shares are trading lower after the company ... Unlock content with Pro Subscription

2 months ago · Source

-21.7%

PepGen shares are trading lower. The company reported Q3 financial results.

News

6 days ago · zacks.com

All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy

PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

4 weeks ago · https://thefly.com

PepGen clinical hold likely to be resolved quickly, says Leerink

PepGen announced that the FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular dystrophy, while the open-label Phase 2 CONNECT1-EDO51 study continues ex...

1 month ago · businesswire.com

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...

2 months ago · businesswire.com

PepGen to Participate in Upcoming Investor Conferences